Valley National Advisers Inc. Reduces Holdings in Gilead Sciences, Inc. $GILD

Valley National Advisers Inc. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 33,353 shares of the biopharmaceutical company’s stock after selling 1,937 shares during the quarter. Valley National Advisers Inc.’s holdings in Gilead Sciences were worth $3,697,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences in the 1st quarter valued at approximately $25,000. Activest Wealth Management grew its position in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences during the 1st quarter valued at $29,000. Colonial Trust Advisors lifted its holdings in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares in the last quarter. Finally, Core Alternative Capital boosted its stake in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the transaction, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. This represents a 2.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This trade represents a 1.66% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 82,000 shares of company stock valued at $9,402,130. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $112.69 on Monday. The business has a 50 day moving average of $114.34 and a 200 day moving average of $109.97. Gilead Sciences, Inc. has a 52 week low of $83.98 and a 52 week high of $121.83. The company has a market cap of $139.83 billion, a PE ratio of 22.45, a P/E/G ratio of 0.77 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm posted $2.01 EPS. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Saturday, September 27th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. Rothschild & Co Redburn lifted their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Finally, JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $117.17.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.